NCT01166698View on ClinicalTrials.gov

Single Centre, Double-blind, Single and Multiple Ascending Inhaled Doses of AZD9819 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
Healthy VolunteersSafetyTolerability
Interventions
DRUG

AZD9819

Inhaled single doses of suspension via SPIRA nebuliser

DRUG

AZD9819

Inhaled multiple doses of suspension via SPIRA nebuliser, once daily for 10 (maximum 14) days

DRUG

Placebo

Inhaled doses of suspension via SPIRA nebuliser given either as single (Part A) or multiple doses (Part B)

Trial Locations (1)

Unknown

Research Site, London

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY